LONDON and RALEIGH, NC, May 24, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc VRNA (“Verona Pharma” or the “Company”) announces that management will present a company overview at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:00 am EDT / 1:00 pm BST.

A webcast of the event will be available through the “Events and Presentations” link on the Investors page of the Company’s website. www.veronapharma.com.

For more information please contact:

About Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrin, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory effects in one compound. The Company has evaluated nebulized ensifentrin for maintenance treatment of COPD in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”). Ensifentrin met the primary endpoint in both the ENHANCE 1 and ENHANCE 2 studies, demonstrating statistically significant and clinically meaningful improvements in lung function. In addition, ensifentrin significantly reduced the rate and risk of COPD exacerbations in the pooled analysis of ENHANCE-1 and ENHANCE-2. Verona Pharma expects to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in the second quarter of 2019.